Regulatory Roundup: FDA Issues Final Guidance to Amend IND Reporting Requirements - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Issues Final Guidance to Amend IND Reporting Requirements

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has issued a final guidance for sponsors and investigators regarding its enforcement of the agency’s final rule, “Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans.” The rule amended IND reporting requirements under 21 CFR part 312 and added safety reporting requirements for persons conducting bioavailability and bioequivalence studies under 21 CFR part 320, states the guidance. The final rule was released in September 2010 and took effect in March 2011. Enforcement of the reporting requirements outlined in the final rule will begin on Sept. 28, 2011. The final guidance replaces the draft guidance that was issued with the rule in September 2010.

The Pharmaceutical Inspection Cooperation Scheme (PIC/S) celebrated its 40th anniversary on May 31, 2011, in Geneva, Switzerland. More than 160 individuals, including FDA Commissioner Margaret Hamburg, from around the world participated in the event. FDA’s participation was unique as it symbolized its recently accepted membership to the cooperation scheme. Also new to PIC/S is the Ukraine State Inspectorate. PIC/S is a global collaboration representing 39 competent authorities and focuses on GMP inspections of pharmaceutical manufacturing sites. PIC/S also works with the European Commission and has partnership agreements with regulatory and global health bodies such as EMA, EDQM, UNICEF, and WHO, and works with industry and academic groups globally on training programs.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here